Publications of the Week, June 28


Colchicine use in community-treated patients with COVID-19

Tardif JC, Bouabdallaoui N, L'Allier PL, et al; COLCORONA Investigators. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021 May 27:S2213-2600(21)00222-8. doi: 10.1016/S2213-2600(21)00222-8. Epub ahead of print. PMID: 34051877; PMCID: PMC8159193.

For a McMaster Perspective interview with Dr Nishma Singhal on the results of the COLCORONA trial, click here.

Background: In patients with coronavirus disease 2019 (COVID-19) pneumonitis, compelling evidence showing that an excessive inflammatory response contributes to morbidity and mortality has prompted the assessment of anti-inflammatory pharmacologic strategies that include glucocorticoids, hydroxychloroquine, heparins, and intereukin-6 inhibitors. Colchicine is an oral anti-inflammatory agent that is typically used to treat patients with acute gout or acute pericarditis.

Methods: This randomized controlled trial assessed the effect of colchicine on the composite outcome of COVID-19-related death or hospitalization. Included patients were adults aged ≥40 years with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria who were not hospitalized and had ≥1 high-risk characteristic (age ≥70 years, body mass index [BMI] ≥30 kg/m2, diabetes, hypertension, respiratory or heart disease, recent fever ≥38.4 degrees Celsius, dyspnea at presentation, or blood count abnormalities). Patients received colchicine 0.5 mg bid for 3 days and once daily thereafter for 27 days, or matching placebo.

Results: A total of 4488 patients were enrolled (53.9% women; median age, 54 years). In the overall study population, there was no significant difference in the primary outcome between the colchicine and placebo groups: 4.7% versus 5.8% (odds ratio [OR], 0.79; 95% CI, 0.61-1.03; P = .081). In 4159 patients with PCR-confirmed COVID-19, the primary endpoint rate was significantly lower in the colchicine group: 4.6% versus 6% (OR, 0.75; 95% CI, 0.57-0.99; P = .042). The risk of COVID-19 pneumonitis was significantly reduced in the colchicine group: 2.9% versus 4.1% (P = .021). There was no significant difference in serious adverse events between the study groups, but diarrhea occurred more often in the colchicine group: 13.7% versus 7.3%; P < .001.

Conclusions: The authors concluded that in nonhospitalized patients with PCR-confirmed COVID-19 colchicine was associated with a lower rate of the composite of death or COVID-19-related hospitalization than placebo. They suggested that this safe and inexpensive anti-inflammatory agent could be considered for use in individuals at risk of COVID-19-related complications.

McMaster editors' comment: This study aligns with the premise that inflammation is a key mediator in the development and clinical progression of COVID-19. The positive results in patients with PCR-confirmed COVID-19 should be tempered by the relatively low absolute risk reduction (1.1%) and high rate of diarrhea among colchicine-treated patients (13.7%). If preventative colchicine use is adopted, patient selection will be needed to identify those most likely to benefit while monitoring for gastrointestinal adverse effects.

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.